BioPorto A/S to host an investor webcast on the results for the first half of 2025

Core Viewpoint - BioPorto A/S will present its financial results for the first half of 2025 during an investor webcast scheduled for August 15, 2025 [1] Company Overview - BioPorto A/S is an in vitro diagnostics company focused on improving patient management through actionable biomarkers [2] - The company specializes in antibody and assay development, aiming to address significant unmet medical needs with its product pipeline [2] Key Products - The flagship products of BioPorto are based on the NGAL biomarker, which aids in the risk assessment and diagnosis of Acute Kidney Injury (AKI) [3] - NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier intervention [3] Market Presence - BioPorto has facilities located in Copenhagen, Denmark, and Boston, MA, USA, and its shares are listed on the Nasdaq Copenhagen stock exchange [4]